Androgen regulates neuritin mRNA levels in an in vivo model of steroid-enhanced peripheral nerve regeneration.
Following crush injury to the facial nerve in Syrian hamsters, treatment with androgens enhances axonal regeneration rates and decreases time to recovery. It has been demonstrated in vitro that the ability of androgen to enhance neurite outgrowth in motoneurons is dependent on neuritin-a protein that is involved in the re-establisment of neuronal connectivity following traumatic damage to the central nervous system and that is under the control of several neurotrophic and neuroregenerative factors--and we have hypothesized that neuritin is a mediator of the ability of androgen to increase peripheral nerve regeneration rates in vivo. Testosterone treatment of facial nerve-axotomized hamsters resulted in an approximately 300% increase in neuritin mRNA levels 2 days post-injury. Simultaneous treatment with flutamide, an androgen receptor blocker that is known to prevent androgen enhancement of nerve regeneration, abolished the ability of testosterone to upregulate neuritin mRNA levels. In a corroborative in vitro experiment, the androgen dihydrotestosterone induced an approximately 100% increase in neuritin mRNA levels in motoneuron-neuroblastoma cells transfected with androgen receptors, but not in cells without androgen receptors. These data confirm that neuritin is under the control of androgens, and suggest that neuritin is an important effector of androgen in enhancing peripheral nerve regeneration following injury. Given that neuritin has now been shown to be involved in responses to both central and peripheral injuries, and appears to be a common effector molecule for several neurotrophic and neurotherapeutic agents, understanding the neuritin pathway is an important goal for the clinical management of traumatic nervous system injuries.
Fargo
Keith N
KN
Neuroscience Program and Department of Cell Biology, Neurobiology and Anatomy, Loyola University Chicago Stritch School of Medicine, Maywood, Illinois, USA. kfargo@lumc.edu
Alexander
Thomas D
TD
Tanzer
Lisa
L
Poletti
Angelo
A
Jones
Kathryn J
KJ
D000726:Androgen Antagonists / Q000494:pharmacology; D000728:Androgens / Q000494:pharmacology*; D000818:Animals; D019771:Axotomy; D006224:Cricetinae; D005154:Facial Nerve / Q000502:physiology*; D005485:Flutamide / Q000494:pharmacology; D008297:Male; D008647:Mesocricetus; D051379:Mice; D009046:Motor Neurons / Q000187:drug effects / Q000378:metabolism; D009416:Nerve Regeneration / Q000187:drug effects*; D009419:Nerve Tissue Proteins / Q000378:metabolism*; D016133:Polymerase Chain Reaction; D012333:RNA, Messenger / Q000032:analysis / Q000187:drug effects; D013739:Testosterone / Q000494:pharmacology*
D000726:Androgen Antagonists; D000728:Androgens; D009419:Nerve Tissue Proteins; D012333:RNA, Messenger; D013739:Testosterone; D005485:Flutamide